TOPPER

Tag Archives | Drugs and Pharmaceuticals

News: Divergent CRO Announces Launch of New Contract Research Organization | CitizenWire

ATLANTA, Ga. /CitizenWire/ — Divergent CRO, a leading provider of clinical services to biotech and device companies, is pleased to announce the official launch of its new Contract Research Organization (CRO). This new venture aims to revolutionize the research and development process by offering comprehensive and tailored clinical services to meet the unique needs of […]

Continue Reading

News: Trends in Drug Benefit Design Report Released by Pharmaceutical Strategies Group (PSG) | CitizenWire

DALLAS, Texas /CitizenWire/ — Pharmaceutical Strategies Group (PSG), an EPIC company, is pleased to announce the launch of its Trends in Drug Benefit Design Report. The report delivers innovative research on the latest trends in the traditional (non-specialty) drug benefit. Sponsored by Rx Savings Solutions, it outlines the complexities of designing and managing the drug […]

Continue Reading

News: PSG Announces Release of Highly Anticipated ‘Trends in Specialty Drug Benefits Report’ | CitizenWire

DALLAS, Texas /CitizenWire/ — Pharmaceutical Strategies Group (PSG), an EPIC company, is pleased to announce the release of its annual Trends in Specialty Drug Benefits report. Delivering visibility into the complexity of the specialty drug landscape, it offers detailed intelligence through proprietary research. PSG has been researching and reporting on drug benefit design for over […]

Continue Reading

News: NEW PRODUCT LAUNCH: Pharmaceutical Strategies Group (PSG) Announces Artemetrx Extend – Revolutionary Drug Management Reporting Tool Offers Powerful User Insights | CitizenWire

DALLAS, Texas /CitizenWire/ — Artemetrx®, the industry’s most preeminent platform for integrated drug cost management, is now even more robust with the launch of its new module, Artemetrx Extend™. With greater insights and analytics, Artemetrx Extend is a custom reporting tool that provides unparalleled data access through its user-friendly platform.

Continue Reading

News: Kalyagen Announces Attendance and Speaking Engagement at 8th Annual Biohacking Conference | CitizenWire

AUSTIN, Texas /CitizenWire/ — Kalyagen is pleased to announce that it will be attending and its founder, Christian Drapeau, will be speaking at the upcoming 8th Annual Biohacking Conference. The conference, which is completely sold out, will be held September 15-17 at The Beverly Hilton in Beverly Hills, California.

Continue Reading

News: Zeteo Biomedical Introduces OrionMRQ™ Nasal Delivery Device for Vaccines | CitizenWire

PFLUGERVILLE, Texas /CitizenWire/ — Zeteo Biomedical LLC announced today the availability of the ZEOx1 OrionMRQ™ nasal drug and vaccine delivery device. Zeteo’s latest innovative delivery device provides pharmaceutical and biotech companies developing drugs, peptides, proteins, monoclonal antibodies and vaccines with precise, metered unit dose systemic delivery via the nasal route.

Continue Reading

News: Oral Vaccine Boosts COVID Immunity: study conducted on nonhuman primates is published in the journal Vaccine | CitizenWire

ROCHESTER, Minn. /CitizenWire/ — Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine.

Continue Reading

News: Myrio Therapeutics and Pure MHC, LLC Announce Research Collaboration to Develop Novel, Targeted Antibody-Based Cancer Therapies | CitizenWire

OKLAHOMA CITY, Okla. /CitizenWire/ — Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC’s proprietary offering of MHC peptide targets for oncology with Myrio’s revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies […]

Continue Reading

News: iCell Gene Therapeutics Announces cCAR-T Clinical Publication in the Stem Cell Reviews and Reports Journal | CitizenWire

STONY BROOK, N.Y. /CitizenWire/ — iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, today announced the publication of their clinical study utilizing cCAR T-cell immunotherapy to successfully treat a patient with lupus.

Continue Reading

News: Kalyagen Announces Release of Free eBook on How to Optimize Health Using Stem Cells | CitizenWire

AUSTIN, Texas /CitizenWire/ — Kalyagen® has announced the release and availability of a free eBook, “The Stemregen Effect – Tapping into the Power of Your Own Stem Cells,” which provides an overview of how stem cells are the body’s repair system and how STEMREGEN®, a natural stem cell enhancer, has been documented to increase the […]

Continue Reading

News: Live-Online C. diff. Symposium developed to support and guide patients, families, and caregivers through a C. difficile illness | CitizenWire

TAMPA, Fla. /CitizenWire/ — The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, July 16, 2021, from 1 to 3 p.m. EDT. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection (CDI) in addition to those who are recovering or […]

Continue Reading

News: Pure MHC, LLC Announces Launch of its Peptide HLA Immunotherapy Data Resource following Collaboration with LifeNet Health | CitizenWire

AUSTIN, Texas /CitizenWire/ — Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource (“PHIDR”), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.

Continue Reading

News: Pure Transplant Solutions Announces Collaboration with the University of Alabama at Birmingham to Develop Memory B Cell-Directed Diagnostics for HLA-Sensitized Patients | CitizenWire

BIRMINGHAM, Ala. /CitizenWire/ — Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with The University of Alabama at Birmingham (UAB), a leading institution in […]

Continue Reading

News: Zeteo Biomedical Receives US Patent for Innovative Sublingual Delivery Device for Vaccines and Pharmaceuticals | CitizenWire

AUSTIN, Texas /CitizenWire/ — Zeteo Biomedical, a privately held, biomedical device company, announced today it has been awarded a United States Patent for its “Oral Delivery Device and Methods” (US Patent 10238577). This latest patent expands the capabilities of Zeteo’s ZEO Delivery Platform to systemically deliver drugs or biologics, into the body non-invasively via the […]

Continue Reading

News: Caisson Biotech, LLC and Heparinex, LLC Announce Positive Examination Report of European Patent and the Discovery of a New Class of Sugar Polymers | CitizenWire

AUSTIN, Texas /CitizenWire/ — Caisson Biotech and parent company Heparinex are pleased to announce that they have received a positive examination report from the European Patent Office for a patent covering the chemoenzymatic production of heparosan utilized in the HEPtune® drug delivery platform. Once certified, the new patent family will increase patent coverage across Europe, […]

Continue Reading

News: Rescindo Therapeutics’ RSC-57 Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Kabuki Syndrome | CitizenWire

CARY, N.C. /CitizenWire/ — Rescindo Therapeutics Inc., a drug discovery company dedicated to the development of new treatments for rare genetic disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation and Rare Pediatric Disease Designation for the Company’s lead drug RSC-57, for the treatment of patients with Kabuki […]

Continue Reading

News: Kalyagen Announces Launch of ‘Stem the Tide of Time’ Campaign Featuring NBA Hall of Fame Finalist Marques Johnson | CitizenWire

AUSTIN, Texas /CitizenWire/ — Kalyagen is pleased to announce the launch of its “Stem the Tide of Time” social media campaign featuring former UCLA Bruin and Milwaukee Buck All-Star Marques Johnson to promote STEMREGEN;, a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).

Continue Reading

News: Kalyagen™ Announces Launch of Clinical Trial to Evaluate STEMREGEN® and Stem Cells for Advanced Heart Failure Patients | CitizenWire

AUSTIN, Texas /CitizenWire/ — Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the “Spanish Society of Regenerative Medicine and Cell Therapy”), is pleased to announce the launch of a multicenter clinical trial, “The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart […]

Continue Reading

News: EPIC Insurance Brokers & Consultants Acquires Pharmaceutical Strategies Group | CitizenWire

SAN FRANCISCO, Calif. /CitizenWire/ — EPIC Holdings, Inc. (EPIC) announced today that it has agreed to acquire Pharmaceutical Strategies Group (PSG). The move incorporates the expertise and resources of the nation’s largest independent pharmacy benefit consulting firm into EPIC’s Employee Benefits Consulting practice.

Continue Reading

News: Zeteo Biomedical to Collaborate with Iowa State University Nanovaccine Institute to Study a COVID 19 Vaccine Under Fast Track CARES Act Funded Program | CitizenWire

AUSTIN, Texas /CitizenWire/ — Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2 Delivery Platform.

Continue Reading

NEWS: NED Biosystems Announces Leading Infectious Disease Research Scientist Michael Mansour, MD, PhD To Serve as Medical Advisor

CAMBRIDGE, Mass., Oct. 6, 2020 (SEND2PRESS NEWSWIRE) — NED Biosystems, an innovative clinical-stage biotech company developing therapies for cancer and the novel coronavirus, is pleased to announce that Michael Mansour, MD, PhD, will serve as the Company’s Medical Advisor of Infectious Disease.

Continue Reading

NEWS: US Pharmaceutical Corporation® Introduces Patented Hylafem® pH Vaginal Suppositories Consisting of Boric Acid in a Probiotic Blend

DECATUR, Ga., Aug. 17, 2020 (SEND2PRESS NEWSWIRE) — US Pharmaceutical Corporation, the probiotic and nutritional supplement company, launches Hylafem pH vaginal suppositories, a unique, patented, homeopathic suppository product which efficaciously tackles recurring women’s vaginal health issues.

Continue Reading

NEWS: A Novel Treatment Approach to Silent Hypoxia in COVID-19 Patients

PARK CITY, Utah, May 26, 2020 (SEND2PRESS NEWSWIRE) — Silent Hypoxia is a frequent disabling and sometimes fatal complication in COVID-19 disease. To prevent SARS-CoV-2 coronavirus-induced damage to patients’ lungs and Silent Hypoxia in patients, Aristea Translational Medicine Corp. has initiated development of PhenT, a drug with novel cellular protective properties.

Continue Reading

NEWS: ROKiT Pharma’s Preclinical Studies Showing Tremendous Promise for Naturally Derived Cancer Drug, ROK-001 – Moving Towards The Initiation Of Phase 1b/2 Clinical Trial

LOS ANGELES, Calif., April 2, 2020 (SEND2PRESS NEWSWIRE) — ROKiT Pharma, Inc., a public-benefit corporation dedicated to putting patients first, announced today it is rapidly progressing through final preclinical studies and moving forward with preparation for the initiation of a Phase 1b/2 clinical trial of ROK-001, a potentially low toxicity cancer drug derived from natural […]

Continue Reading

NEWS: EPIC Continues Expansion of Employee Benefits Practice with a new Pharmacy Practice Leader

SAN FRANCISCO, Calif. and NEW YORK, N.Y., Feb. 3, 2020 (SEND2PRESS NEWSWIRE) — EPIC Insurance Brokers and Consultants, a retail property, casualty insurance brokerage and employee benefits consultant, announced today they are continuing to expand their employee benefits resources with the addition of a new Pharmacy Practice Leader, Bob Eisendrath.

Continue Reading

NEWS: iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations at 61st American Society of Hematology Annual Meeting

STONY BROOK, N.Y., Nov. 14, 2019 (SEND@PRESS NEWSWIRE) — iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, announced today that it will give oral and poster presentations related to its BCMA-CD19 cCAR and CD4-specific CAR programs at the 61st American Society of […]

Continue Reading

NEWS: C Diff Foundation Raises Clostridioides difficile Awareness in St. Louis on Nov. 6-7 at 7th Annual International Conference and Health EXPO

ST. LOUIS, Mo., Oct. 14, 2019 (SEND2PRESS NEWSWIRE) — C Diff Foundation announced today that the 7th Annual International C. diff. Conference and Health EXPO is honored to welcome over 30 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies. November 6 – 7, 2019 at the DoubleTree by Hilton Westport […]

Continue Reading

NEWS: 2019 Lupus Insight Prize Awarded to Dr. Ignacio Sanz: Recognizes Studies of Harmful Immune Cells in Lupus

BOSTON, Mass., June 19, 2019 (SEND2PRESS NEWSWIRE) — The Lupus Research Alliance has awarded its 2019 Lupus Insight Prize to Ignacio Sanz, MD, for discovering that certain little-understood immune system cells are a major source of the harmful proteins that promote lupus symptoms. His work could spark new treatments for the disease and help doctors […]

Continue Reading

NEWS: C Diff Foundation Recognizes Rebiotix CEO with 2019 ‘Above and Beyond’ Award

NEW PORT RICHEY, Fla., Jan. 29, 2019 (SEND2PRESS NEWSWIRE) — The C. Diff Foundation Board of Directors announced today that the 2019 “Above and Beyond” Award will be presented to Rebiotix CEO Lee Jones in Roseville, Minnesota. The award, given to one recipient annually, is given to a person or organization that show extraordinary dedication […]

Continue Reading
C Diff Foundation Annual Conference

NEWS: Leading Companies to Support C Diff Foundation 6th Annual International C.diff. Conference and Health EXPO, Nov. 8-9, Philadelphia

PHILADELPHIA, Pa., Oct. 31, 2018 (SEND2PRESS NEWSWIRE) — The C Diff Foundation is honored to welcome leading companies to the 6th Annual International “C.diff. Awareness Conference and Health EXPO,” as they come together to make a global difference. These companies are dedicated to the prevention, diagnostics, treatments, environmental safety products and services focused on C.difficile […]

Continue Reading
Healthcare Tech and Delta Care Rx

NEWS: Healthcare Tech Outlook Names Delta Care Rx a Top 10 Pharmacy Management Solution Provider

FREMONT, Calif., April 23, 2018 (SEND2PRESS NEWSWIRE) — Delta Care Rx, a leading pharmaceutical innovator in end of life care, has been named one of the “Top 10 Pharmacy Management Solution Providers of 2018,” according to Healthcare Tech Outlook, a digital and print magazine publication of Valley Media, Inc.

Continue Reading
Koch Kellan Scholar Alejandro Arboleda

NEWS: Alejandro Arboleda Named 2018 Koch Kellan Scholar

PORTLAND, Ore., April 13, 2018 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., an ophthalmic pharmaceutical and medical device company, announced today that Alejandro Arboleda has been named its 2018 Koch Kellan Scholar. Paragon Gives, a Paragon BioTeck initiative, awards the Koch Kellan Scholarship to an outstanding graduate medical student committed to elevating the standard of eye […]

Continue Reading
C DIFF Foundation and CutisPharma

NEWS: C Diff Foundation Presents Award to CutisPharma in Recognition of Contribution to C. diff. Community

NEW PORT RICHEY, Fla., March 16, 2018 (SEND2PRESS NEWSWIRE) — The C Diff Foundation announced today that it presented CutisPharma, Inc., its “Making a Difference” award as a special recognition of the significant contribution that CutisPharma has made to the C.diff. Community: helping the advancement of C.diff. awareness as well as expanding treatment options for […]

Continue Reading

Part of the Neotrope® News Network, USA.